RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

<p>BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) — RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, today announced that it has entered into definitive agreements for the purchase […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/rvl-pharmaceuticals-plc-announces-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules/">RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>